Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

Adagrasib Discovered for the Treatment of Advanced Non-Small Cell Lung Cancer

Mirati Therapeutics discovered novel therapy, Adagrasib for the treatment of patients with non-small cell lung cancer (NSCLC) harbouring the KRASG12C Mutation.

Adagrasib is an investigational, selective and oral small-molecule inhibitor of KRASG12C which is developed to support target inhibition, as KRASG12C protein regenerates every 24-48 hours.

In several clinical trials, Adagrasib is currently being evaluated in combination with other anti-cancer therapies with strong scientific rationale for patients with advanced solid tumors.

Lung cancer is the most common type of cancer reaching 2.21 million new cases and 1.8 million deaths globally. Among lung cancers, nearly 85 percent cases result in non-small cell lung cancer (NSCLC) and about 15 percent cases result in small cell lung cancer (SCLC).

KRASG12C is the most common mutation found in non-small cell lung cancer (NSCLC), found among 14 percent of patients with lung adenocarcinoma.

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinRehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024